REPORT

Mosaicism of the UDP-Galactose Transporter *SLC35A2* Causes a Congenital Disorder of Glycosylation

Bobby G. Ng,[1] Kati J. Buckingham,[2] Kimiyo Raymond,[3] Martin Kircher,[4] Emily H. Turner,[4] Miao He,[5] Joshua D. Smith,[4] Alexey Eroshkin,[1] Marta Szybowska,[6] Marie E. Losfeld,[1] Jessica X. Chong,[2] Mariya Kozenko,[6] Chumei Li,[6] Marc C. Patterson,[7] Rodney D. Gilbert,[8] Deborah A. Nickerson,[4] Jay Shendure,[4] Michael J. Bamshad,[2,4] University of Washington Center for Mendelian Genomics and Hudson H. Freeze[1,*]

Biochemical analysis and whole-exome sequencing identified mutations in the Golgi-localized UDP-galactose transporter *SLC35A2* that define an undiagnosed X-linked congenital disorder of glycosylation (CDG) in three unrelated families. Each mutation reduced UDP-galactose transport, leading to galactose-deficient glycoproteins. Two affected males were somatic mosaics, suggesting that a wild-type *SLC35A2* allele may be required for survival. In infancy, the commonly used biomarker transferrin showed abnormal glycosylation, but its appearance became normal later in childhood, without any corresponding clinical improvement. This may indicate selection against cells carrying the mutant allele. To detect other individuals with such mutations, we suggest transferrin testing in infancy. Here, we report somatic mosaicism in CDG, and our work stresses the importance of combining both genetic and biochemical diagnoses.

Congenital disorders of glycosylation (CDGs) are a group of more than 60 mainly autosomal recessive disorders caused by impaired synthesis of glycoconjugates.[1] Affected individuals often have profound neurological deficiencies, including intellectual disability, seizures, and a wide range of multiorgan symptoms.[2] The majority of CDG defects involve the N-linked glycosylation pathway, and alterations can be detected by abnormal glycosylation of the convenient biomarker serum transferrin (Tf).[3,4]

All clinical samples were obtained with proper informed consent in accordance with the Sanford-Burnham Medical Research Institute's institutional review board consent guidelines.

We identified an affected male (CDG-341) with an unusual Tf profile in comparison to a healthy control who showed loss of both galactose and sialic acid from multiple branches of complex type N-glycans (Figures 1A and 1B). Sanger sequencing of candidate genes encoding proteins in the glycosylation pathway identified hemizygosity for frameshift mutation c.15_91+48delinsA (p.Gly8Serfs*9) in *SLC35A2* (MIM 314375, RefSeq: NM_001042498.2) (Table 1, Figure S1A available online). This X-linked gene encodes the single known Golgi-localized UDP-galactose transporter. CDG-341 had a 46 XY karyotype, suggesting that he was a somatic mosaic, given that he carried both wild-type (WT) and mutant *SLC35A2* alleles. This finding motivated us to examine exome sequencing (ES) data from 16 unrelated individuals with unclassified CDG and abnormal Tf profiles.

Two of these cases (CDG-348 and CDG-352) had Tf profiles similar to CDG-341 that showed loss of both galactose and sialic acid. One of these cases (CDG-348), a female, was heterozygous for a c.3G>A missense variant in the initiation codon (p.Met1?) that eliminated the normal start site (Table 1, Figure S1B). However, using our standard exome filtering pipeline, we did not find any mutations in *SLC35A2* in a male individual, CDG-352, nor was he homozygous or compound heterozygous for rare variants in known CDG-causing genes. Motivated by the unique Tf pattern, we performed a manual review of all variants in CDG-352 to determine whether candidate variants had been excluded by one of the GATK filter flags. This review revealed a c.991G>A missense variant predicted to cause a deleterious substitution (p.Val331Ile) in the last transmembrane domain of SLC35A2 (Table 1, Figure S1C). This variant had been excluded in our standard pipeline because of a low genotype quality value of 16.99 (standard cutoff value ≥ 75). Furthermore, 9% of the *SLC35A2* alleles identified in CDG-352 at the variant site were reference alleles, suggesting somatic mosaicism for p.Val331Ile. Sanger sequencing confirmed this observation (Figure S1C).

None of these mutations were present in the Single Nucleotide Polymorphism database, 1000 Genomes, or the NHLBI Exome Variant Server (EVS), the latter of which consists of SNVs found in >13,000 chromosomes from European Americans (n = 8600) and from African Americans (n = 4406). Sanger sequencing of the unaffected parents confirmed that all of these *SLC35A2* mutations arose de

Figure 1. Electrospray Ionization Mass Spectrometry Analyses of Whole Serum Tf from the Control Sample and Individual CDG-341

(A) Serum Tf from an unaffected control.
(B) CDG-341 at 5 months of age showing loss of both galactose and sialic acid from multiple branches of complex type N-glycans.
(C) CDG-341 at 38 months of age showing that Tf glycosylation has become normal.

novo (Table 1, Figures S1A–S1C). Collectively, these results were compelling evidence that mutations in *SLC35A2* cause a CDG subtype with unique biochemical and genetic features.

Both affected males were hemizygous for their de novo mutation, but they also retained a functional allele, indicating somatic mosaicism for the mutant *SLC35A2* allele. This observation suggests that the retention of a functional *SLC35A2* allele might be required for survival and that deleterious alleles might be less tolerated in males than in females. To test this, we categorized each variant in the NHLBI Exome Sequencing Project (ESP)6900 data set as putatively deleterious if the variant was annotated by SeattleSeq134 as creating a stop loss or frameshift mutation or if the variant had a genomic evolutionary rate profiling score ≥ 3.0. To control for different numbers of males (N = 2,602) and females (N = 4,190) as well as different gene lengths, we analyzed the proportion of variants in a gene that were deleterious.

Consistent with this hypothesis, the proportion of *SLC35A2* alleles predicted to be deleterious was both higher in females (0.41) in comparison to males (0.25) and ranked higher among all genes on the X chromosome in females (358, 713th) in comparison to males (256, 704th) in the NHLBI ESP data set (Figure S2).

To test whether each of these variants in *SLC35A2* altered galactosylation, we analyzed glycans from primary fibroblasts and whole serum of each individual. Loss of SLC35A2 severely limits Golgi-localized pools of UDP-galactose, resulting in truncated β-GlcNAc-terminated N-glycans and α-GalNAc-terminated O-glycans. These changes predict increased binding to the lectins GSII (*Griffonia simplicifolia*) for terminal β-GlcNAc on N-glycans and to VVA (*Vicia villosa*) for terminal α-GalNAc on O-gly-cans.[5–7] Flow cytometry analysis with fluorescently tagged lectins proves that all affected individual fibroblast lines fit the predictions, indicating incomplete galactosylation, which leads to incomplete sialylation. (Figure 2)

We directly measured the transport of UDP [6-³H]-galac-tose into the Golgi using streptolysin-O-permeabilized fibroblasts to preserve intact Golgi and SLC35A2 transporter activity.[8] Despite having a mixed population of both WT and mutant cells, all three individuals had considerably reduced UDP-galactose transport when compared to control cells (Figure 3).

UDP [6-³H]-galactose transport assays with a 90% pure population of CDG-341-GSII-sorted mutant fibroblasts showed a further 20% decrease in activity and not its elimination (data not shown). This supports the presence of an alternate UDP-galactose transporter that accounts for the activity.

Analysis of N-glycans from whole serum by MALDI-TOF mass spectrometry also showed increased levels of hypoga-lactosylated glycans, particularly biantennary species (Figure S3). Given that cells from CDG-348 and CDG-341 must have either a normal allele with complete galactosy-lation or a functionally null allele with no galactosylation at all, the presence of a substantial amount of partially galactosylated glycans on serum glycoproteins further suggests the possible existence of a previously unrecog-nized UDP-gal transporter.

Other studies suggest that a normal UDP-GlcNAc trans-porter, SLC35A3 [MIM 605632], can also improve galacto-sylation in the UDP-galactose-deficient CHO cell line LEC8. Furthermore, many putative nucleotide sugar trans-porters are incompletely characterized.[9]

The clinical phenotypes and severity of biochemical defects of these individuals varied substantially (Table 1). Nevertheless, at 5–7 months of age, all individuals had similar galactosylation-deficient Tf profiles; but a sample obtained from CDG-348 at 3 years of age showed a nearly normal pattern without clinical improvement (Figure S4). Samples taken at an older age in both CDG-352 (5 years of age) and CDG-341 (3 years of age) (Figure 1C) were also completely normal. This normalization in all three individuals suggests that SLC35A2-CDG cases

Table 1. Clinical Presentation and SLC35A2 Mutations Identified in Three Families with CDG Type IIx

	CDG-341	CDG-348	CDG-352
Ancestry	European	European	European
Gender	Male	Female	Male
Current Age	3 years	3 years	6 years
Inheritance	de novo	de novo	de novo
Nucleotide Change	chrX: 48,768,775_48,768,899 delinsT	chrX: 48,768,911 C>T	chrX: 48,762,195 C>T
cDNA Change	c.15_91+48 delinsA	c.3G>A	c.991G>A
Protein Change	p.Gly8Serfs*9	p.Met1?	p.Val331Ile
Likely Affect on Protein	Termination	Loss of initiator methionine	Improper positioning in membrane
Developmental Delay	Yes	Yes	Yes
Hypotonia	Yes	Yes	Yes
Seizures	Yes	Yes	No
Hypsarrhythmia	Yes	Yes	No
Hypertension	No	No	Yes
Dysmorphic features	No	Yes	Yes
Skeletal abnormalities	No	Shortened extremities	Shortened extremities
Renal	No	No	Acute nephrotic syndrome; requiring dialysis
Ocular	Nystagmus	Retinitis pigmentosa	Ocular flutter
Liver dysfunction	No	No	No
Coagulopathy	Yes	No	No
Gastrointestinal	No	Strictly G-tube feed	Gastro-esophageal reflux, esophagitis, duodenal perforation
Recurrent Infections	No	Yes	No
Microcephaly	No	Yes	Yes
Brain malformation	Small cerebellum	Thinning of corpus callosum with delayed myelinization	Cerebral hypoplasia/atrophy

could have a limited abnormal Tf diagnostic window, and, without that biochemical lead, standard exome analysis would have discounted the complex results from these somatic mosaics. Accordingly, individuals suspected of having a CDG should be tested for abnormal Tf as early in life as possible. In each individual, it is very likely that Tf testing would have been normal had it been delayed, making diagnosis of a CDG much more challenging.

One explanation for the normalized Tf profiles is that hepatocytes carrying the mutant allele are selected against during infancy. In support of this, we found that GSII-enriched fibroblasts (CDG-341) containing the mutant allele grew ~25% slower than cells with a WT allele (data not shown). Moreover, DNA prepared from peripheral blood leukocytes had nearly undetectable levels of the mutant allele (data not shown). Again, this suggests possible selection against abnormal cells.

We tried to improve galactosylation in each fibroblast line by providing 150–300 uM galactose for between 2– 4 days, but we saw no significant improvement in GSII binding.

Our study highlights the importance of combining biochemical data and detailed knowledge of glycosylation pathways to narrow the candidate genes from ES. We suggest that this approach will help solve the other glycosylation disorders, even if Tf was not analyzed or was uninformative. Heightened awareness of glycobiology and the accelerating discovery of new glycosylation disorders by ES will enhance both basic science and medical practice.[10,11]

Figure 2. Cell-Surface Analysis of Deficient Galactosylation and Increased Terminal β-GlcNAc and α-GalNAc

(A) Flow cytometry analysis of Alexa-647-conjugated GSII (*Griffonia simplicifolia*) lectin in control and individual fibroblasts showing increased lectin binding in all three individuals. The parallel control is representative of three different lines that were tested.

(B) Flow cytometry analysis of fluorescein-labeled VVA (*Vicia Villosa*) lectin in control and individual fibroblasts also showing increased binding in all three individuals. The parallel control is representative of three different lines that were tested.


Figure 3. SLC35A2 Transport Activity in Fibroblasts from Both Control and Affected Individuals

Golgi transport of UDP [6-^{3}H]-galactose in streptolysin-O permeabilized fibroblasts from controls and affected individuals. Each data point was done in duplicate, and error bars were calculated by SD.

Web Resources

The URLs for data presented herein are as follows:

1000 Genomes Project, http://www.1000genomes.org/

NHLBI Exome Sequencing Project (ESP) Exome Variant Server, http://evs.gs.washington.edu/EVS

Online Mendelian Inheritance in Man (OMIM), http://www.omim.org/

The Single Nucleotide Polymorphism database (dbSNP), http://www.ncbi.nlm.nih.gov/SNP/

References

1. Hennet, T. (2012). Diseases of glycosylation beyond classical congenital disorders of glycosylation. Biochim. Biophys. Acta *1820*, 1306–1317.

2. Freeze, H.H., Eklund, E.A., Ng, B.G., and Patterson, M.C. (2012). Neurology of inherited glycosylation disorders. Lancet Neurol. *11*, 453–466.

3. Lacey, J.M., Bergen, H.R., Magera, M.J., Naylor, S., and O'Brien, J.F. (2001). Rapid determination of transferrin isoforms by immunoaffinity liquid chromatography and electrospray mass spectrometry. Clin. Chem. *47*, 513–518.

4. Freeze, H.H. (2006). Genetic defects in the human glycome. Nat. Rev. Genet. *7*, 537–551.

5. Maszczak-Seneczko, D., Olczak, T., Wunderlich, L., and Olczak, M. (2011). Comparative analysis of involvement of UGT1 and UGT2 splice variants of UDP-galactose transporter in glycosylation of macromolecules in MDCK and CHO cell lines. Glycoconj. J. *28*, 481–492.

6. Deutscher, S.L., and Hirschberg, C.B. (1986). Mechanism of galactosylation in the Golgi apparatus. A Chinese hamster ovary cell mutant deficient in translocation of UDP-galactose across Golgi vesicle membranes. J. Biol. Chem. *261*, 96–100.

7. Miura, N., Ishida, N., Hoshino, M., Yamauchi, M., Hara, T., Ayusawa, D., and Kawakita, M. (1996). Human UDP-galactose translocator: molecular cloning of a complementary DNA that complements the genetic defect of a mutant cell line deficient in UDP-galactose translocator. J. Biochem. *120*, 236–241.

8. Wu, X., Steet, R.A., Bohorov, O., Bakker, J., Newell, J., Krieger, M., Spaapen, L., Kornfeld, S., and Freeze, H.H. (2004). Mutation of the COG complex subunit gene COG7 causes a lethal congenital disorder. Nat. Med. *10*, 518–523.

9. Maszczak-Seneczko, D., Sosicka, P., Majkowski, M., Olczak, T., and Olczak, M. (2012). UDP-N-acetylglucosamine transporter and UDP-galactose transporter form heterologous complexes in the Golgi membrane. FEBS Lett. *586*, 4082–4087.

10. National Research Council. (2012). Transforming Glycoscience: A Roadmap for the Future (Washington, D.C.: The National Academies Press).

11. Freeze, H.H. (2013). Understanding Human Glycosylation Disorders: Biochemistry Leads the Charge. J. Biol. Chem., Epub. http://www.jbc.org/cgi/doi/10.1074/jbc.R112.429274.